Shyra Gardai
Chief Scientific Officer EpiBiologics
Seminars
Thursday 12th March 2026
Presenting the Journey to the Clinic for a Novel Bispecific Antibody EpiTAC that Selectively Degrades EGFR in Tumours
12:00 pm
- EPI-326 is a bispecific EGFR EpiTAC that drives targeted degradation of mutant and wild type EGFR specifically within tumours
- Highlighting deep and durable efficacy, favourable safety and PK, and path to IND and clinic for EPI-326
- Demonstrating preclinical advancements with in vivo data on additional programs, emphasising catalytic degrader mechanisms and tissue-specific delivery
- Exploring the transformative potential of bispecific antibody degraders for oncology and inflammatory diseases
